AI’s impact on biotech will unfold at more than one speed
LinkedIn caption
🤖 AI’s impact on biotech will unfold at more than one speed
At ARDD 2026, Kan Chen of Qiming Venture Partners described investment in both foundation-model companies and AI-native biotechs. The official recap captures his expectation that AI will reshape preclinical work, while its effect on company financial performance will take longer to emerge.
💡 That distinction adds a useful time horizon to the discussion: changes in discovery workflows and durable business results need to be evaluated separately. The growth-stage panel connected that question with proprietary data, practical applications and the evidence behind investable therapeutic programs.
#ARDD2026 #AI #Biotech
X caption
🤖 Kan Chen of Qiming Venture Partners highlighted two timelines at #ARDD2026: AI could reshape preclinical work before the financial impact becomes clear. A useful lens on foundation models and AI-native biotechs. Development and business results can follow different timelines.
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
